ENA Recognized as Specialist Affiliate with International Council of Nurses
ICN involvement allows collaboration with international nursing groups
SCHAUMBURG, Ill., April 21, 2025 /PRNewswire/ -- Dedicated to reaching emergency nurses worldwide, the Emergency Nurses Association was recently granted specialist affiliate status by the International Council of Nurses.
'Gaining the specialist affiliate status is a milestone in ENA history,' said ENA President Ryan Oglesby, PhD, MHA, RN, CEN, CFRN, NEA-BC. 'Being part of an international nursing organization of ICN's stature acknowledges ENA as a truly global organization and validates our place as a leader of emergency nursing in the global nursing community.'
The International Council of Nurses is a federation of more than 130 national nursing associations, representing over 28 million nurses worldwide. Founded in 1899, ICN is the world's first and most far-reaching international organization for health professionals and it is one of the most influential voices in nursing. In addition to national nursing association members, ICN grants affiliate status to specialty nursing organizations that are aligned with its mission, maintain a broad international membership, and provide expertise on key global priorities.
The ICN grants affiliate status to international specialist nursing organizations that:
As a Specialist Affiliate, ENA and its nearly 45,000 members across more than 45 countries gain a stronger voice in the global nursing community. The affiliation enhances ENA's ability to influence international health policy, collaborate with national nursing associations, exchange best practices and elevate emergency care worldwide.
ENA will further its global engagement by participating in the ICN Congress 2025 in Helsinki, Finland, joining more than 5,000 nurses from around the world under the inspiring theme: 'Nursing Power to Change the World.'
About the Emergency Nurses Association
The Emergency Nurses Association is the premier professional nursing association dedicated to defining the future of emergency nursing through advocacy, education, research, innovation, and leadership. Founded in 1970, ENA has proven to be an indispensable resource to the global emergency nursing community. With nearly 45,000 members worldwide, ENA advocates for patient safety, develops industry-leading practice standards and guidelines, and guides emergency health care public policy. ENA members have expertise in triage, patient care, disaster preparedness, and all aspects of emergency care. Additional information is available at www.ena.org.
ENA Media Contact:
Morgan Wietecha
Media Relations Strategist
847.460.4038
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/ena-recognized-as-specialist-affiliate-with-international-council-of-nurses-302432873.html
SOURCE Emergency Nurses Association
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
a day ago
- Medscape
Nurse Practitioner Identity and Recognition Key to Success
Over time, the public has begun increasingly recognizing and embracing nurse practitioners as healthcare providers. Perhaps that's not surprising, with more than 385,000 licensed nurse practitioners delivering care in the United States. The US Bureau of Labor Statistics even includes nurse practitioners among what it says will be the top 20 fastest growing occupations in the United States from 2023 to 2033. And nurse practitioners are increasingly common in rural areas, where physician shortages persist. 'I think we've come a long way,' said Ulrike Muench, PhD, MSN, an associate professor at the University of California, San Francisco's School of Nursing. 'Patients are more used to seeing nurse practitioners now for their primary care needs.' She continued, 'But at the same time, I think many times that people are not aware if they are seeing a doctor or seeing a nurse practitioner.' Many experts agree there's still room for improvement when it comes to nurse practitioners getting recognized for their unique role. 'I think we should be recognized as nurse practitioners, practicing at the full scope of our licenses, practicing as an integral part of the healthcare team,' said Kelly Keefe Marcoux, PhD, CPNP-AC, PPCNP-BC, CCRN, an executive board member for the National Association of Pediatric Nurse Practitioners. Creating a New Professional Identity The first people who must recognize the unique identity of nurse practitioners are the people who become nurse practitioners themselves. Although their role is informed by the nursing perspective, it's still a new role. And, as they transition into it, they have to make a mental shift. 'You're so invested as a bedside nurse. You're very competent at that point. You know what you're doing and the expectations and how to deliver on them,' said Keefe Marcoux. 'Then you become a nurse practitioner and all of a sudden, your responsibility shifts.' Marcoux, who has been a pediatric nurse practitioner for 30 years, remembers making that shift. For example, instead of maintaining central lines, Keefe Marcoux found herself inserting central lines. She was no longer giving antibiotics; she was deciding when antibiotics were necessary for patients and which antibiotics to prescribe. 'It's a very different perspective,' she said. Rhoda Owens, PhD, RN It does take some time to make that mental shift, noted Rhoda Owens, PhD, RN, president of the International Society for Professional Identity in Nursing and an associate professor at the University of North Dakota. Her own research found that it took new rural nurse practitioners a year after finishing their formal education to begin to really feel like a nurse practitioner. Plus, as the authors of a 2021 study in Nurse Education in Practice noted, maturity in thinking and experience will continue to drive a nurse's professional identity over time. '[P]rofessional identity is a dynamic and flexible process leading to a growth in understanding about professional practice and a commitment to the profession,' they wrote. Finding a mentor can also help nurse practitioners as they develop and nurture their professional identity, according to Anne Derouin, DNP, APRN, CPNP-PC, PMHS, vice dean of academic and student affairs and clinical professor at the Duke University School of Nursing in Durham, North Carolina. 'This mentor could be a physician colleague who says, 'I want you to come work with me.' But it can also be another advanced practice nurse who's already in that role,' she said. 'They should definitely think of their (nursing school) faculty as mentors, too.' 'We're Not Physicians' One challenge that has persisted: the comparison of nurse practitioners to physicians. Both are considered providers, in that they both provide patient care. But the training requirements are different, and the approach toward care is different. Carole Mackavey, DNP, MSN, RN, FNP-C 'We're not physicians,' said Carole Mackavey, DNP, MSN, RN, FNP-C, master's program coordinator and the post master's nursing education track coordinator at the Cizik School of Nursing at UTHealth Houston, Texas. 'We don't try to be physicians, and we don't think we are. But we can fill a role in primary care as a very valuable member of the healthcare team.' Added Keefe Marcoux, 'We are our own entity, providing a very valuable service.' Many nurse practitioners explain that they consider themselves partners with physicians, not replacements. 'We are in this together, and we have a unified goal of providing care to everyone who needs it,' said Derouin. She often explains that partnership to patients and families, letting them know if they want to see a physician, she can connect them with one. Healthcare system leadership can help alleviate some confusion and ensure that nurse practitioners are recognized for what they do — and that patients understand that nurse practitioners are educated and prepared to provide care. 'I think it's really important that the facility they work for portrays them as a provider,' said Owens. That includes making sure that everyone, from the leaders to the physicians to the medical assistants to the receptionists, understands and uses the appropriate language to refer to nurse practitioners. 'I think just using that terminology will help,' Owens said. Another Complicating Factor Another complicating factor is the lack of consistency for what nurse practitioners are legally able to do, noted Mackavey. 'There is no standard scope of practice,' she said. 'It varies from one state to another.' Nurse practitioners now have full practice authority in 28 states, meaning they're not required to work under a supervising physician. But even in those states, they are not guaranteed equal reimbursement for the same services as provided by a physician. In the wake of COVID-19, many began calling for reimbursement parity for nurse practitioners, noting that the pandemic illustrated how the temporary removal of restrictions to practice led to greater access to care for more people. For example, in 2022, the National Association of Pediatric Nurse Practitioners issued a statement, saying, 'NPs are recognized as independently licensed providers of primary, specialty, and acute care and have demonstrated the ability to provide high-quality health care and incur the same overhead costs as physicians providing care to patients. Therefore, it is imperative that NPs be reimbursed commensurate with physicians for the services they deliver across all federal, state, and health care agency payers and settings, including telehealth.' Advocates continue to call for legislation to enable nurse practitioners to be able to practice at the top of their scope of practice and training, which research suggests is necessary to provide access to quality healthcare. Their education and preparation are what should enable them to have full practice authority, they say. 'It should not vary by state, but rather the education, certification, and experience of nurse practitioner practice (that) prepares them for full practice authority,' said Keefe Marcoux.
Yahoo
3 days ago
- Yahoo
Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies, Published in Journal of Hematology & Oncology
CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from the Phase 1/2 study (KL264-01/MK-2870-001) evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) as monotherapy were published in the international medical journal, Journal of Hematology & Oncology (Impact Factor (IF) = 29.9). Published results include those from the Phase 1 dose-escalation part of the study which evaluated sac-TMT in advanced solid tumors, and those from the Phase 2 expansion cohorts of the study, evaluating sac-TMT in metastatic triple-negative breast . The results of the study demonstrated the therapeutic potential of sac-TMT in this patient population. Results KL264-01/MK-2870-001 is a Phase 1/2 first-in-human trial of sac-TMT as monotherapy in patients who have an unresectable locally advanced or metastatic solid tumor which is refractory to standard therapies, which is a global multi-centre study. Presented results include those from the Phase 1 portion of this study, and the Phase 2 expansion cohorts for TNBC and HR+/HER2– breast cancer. The results of the study showed that sac-TMT demonstrated a manageable safety profile in patients with unresectable locally advanced/metastatic solid tumors and promising antitumor activity in metastatic TNBC and HR+/HER2− breast cancer. Currently, sac-TMT is being investigated in several Phase 3 studies in China, led by the Company, as well as globally, where MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) holds the exclusive rights. In May 2022, the Company licensed the exclusive rights to MSD to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macau, and Taiwan). About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macau, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT became the first domestically developed and fully approved-for-marketing ADC in China with global intellectual property rights. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the NMPA, and were included in the priority review and approval process. As of today, Kelun-Biotech has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech（ a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC or novel DC aseets in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
06-06-2025
- Yahoo
The BC Centre for Excellence in HIV/AIDS national Summit raises alarm about rising incidence of HIV in Canada and threats to global progress
Delegates call on Prime Minister to end the Canadian epidemic and lead the worldwide HIV response in light of dramatic US cuts to treatment and care VANCOUVER, BC, June 6, 2025 /CNW/ - The BC Centre for Excellence in HIV/AIDS (BC-CfE) is hosting a national Summit of medical and HIV experts to raise the alarm about the rising incidence of HIV in Canada, the immense threat that US cuts to HIV programs pose to millions at risk of disease and death globally, and the need for Canadian leadership to help prevent a resurgence in HIV/AIDS. Despite the groundbreaking work done to implement the BC-CfE's Treatment as Prevention® (TasP®) and HIV Pre-Exposure Prophylaxis (PrEP) programs in many jurisdictions, Canada is losing ground to HIV/AIDS across the country. The latest available government statistics for 2023 show a 35% uptick in HIV cases in Canada compared to 2022. Anecdotal discussions between BC-CfE and HIV experts across Canada indicate the situation continues to deteriorate, with HIV incidence statistics expected to be higher yet again in 2024 and in 2025. Meanwhile, the United States has substantially decreased funding to domestic programs currently supported by the US Centers for Disease Control and Prevention and Medicare, and international programs supported by PEPFAR (the US President's Emergency Plan for AIDS Relief) and USAID. UNAIDS estimates another 6.6 million new HIV infections and 4.2 million AIDS-related deaths between 2025 and 2029 if US government cuts continue. At the National TasP Summit, Dr. Julio Montaner, BC-CfE Executive Director & Physician-in-Chief, called on Prime Minister Mark Carney to take the reins and redouble efforts to end the Canadian HIV/AIDS epidemic by 2030, fully fund Highly Active Antiretroviral Therapy (HAART) and PrEP within a national pharmacare plan, and meet the UNAIDS 95-95-95 target for HIV testing, treatment and viral suppression. Meeting the UNAIDS targets* would result in a 90% reduction in HIV/AIDS-related deaths and new infections by 2030, ending the HIV/AIDS epidemic as a public health threat. "The Prime Minister has called for cost-effective, nation-building projects to improve the lives of Canadians and show leadership," said Dr. Montaner. "Redoubling efforts to defeat HIV/AIDS in Canada by 2030 fits the bill. It saves lives, prevents disease progression, improves quality of life and saves money. We have a plan. We need the Prime Minister's help to get it over the finish line." In addition, Canada must step up to better support the Global Fund to Fight AIDS, Tuberculosis and Malaria, to provide much-needed international leadership in a renewed and reinvigorated fight against HIV/AIDS. Weakening global efforts for HIV prevention, treatment, and support are already having an impact in British Columbia and throughout Canada. Domestically, HIV prevention and treatment strategies have saved countless lives and dramatically improved the lives of people living with and at-risk of HIV. However, many of Canada's new HIV cases relate to domestic and international migration, demonstrating the need for federal unity in Canada's HIV response and better support for the Global Fund. "HIV does not respect provincial, Canadian or international borders," said Summit co-chair Dr. Val Montessori, BC-CfE Director of Clinical Education. "With new HIV diagnoses rising across Canada, the need is greater than ever to implement proven HIV prevention and treatment strategies. By working together, we can strengthen the national HIV response in Canada and around the world, improve the lives of people living with HIV, and prevent new cases." *About the UNAIDS 95-95-95 Targets Based on the Treatment as Prevention strategy developed by the BC-CfE, the United Nations Joint Programme on HIV/AIDS (UNAIDS) set out ambitious targets in 2014 to end the AIDS epidemic globally by 2030. This culminated in the UN 95-95-95 Targets, which established that countries ensure 95% of people living with HIV are diagnosed, 95% of those diagnosed are on treatment, and 95% of those on treatment are virally suppressed, by the year 2025. Meeting the UN Targets would change the trajectory of the epidemic so that we would see a 90% reduction in HIV/AIDS related deaths and new HIV infections by 2030, which would herald the end of the HIV/AIDS epidemic as a public health threat. About the British Columbia Centre for Excellence in HIV/AIDS The BC Centre for Excellence in HIV/AIDS (BC-CfE) is Canada's largest HIV/AIDS research, treatment and education facility – nationally and internationally recognized as an innovative world leader in combating HIV/AIDS and related diseases. The made-in-BC Treatment as Prevention® strategy (TasP®) pioneered by BC-CfE, and adopted by UNAIDS since 2011, inspired the ambitious global target for HIV treatment – known as the United Nations' 90-90-90 Target by 2020 and current UN 95-95-95 Target by 2025 – to end AIDS as a pandemic by 2030. The BC-CfE is applying TasP® to therapeutic areas beyond HIV/AIDS, including viral hepatitis and addiction, to promote Targeted Disease Elimination® as a means to contribute to healthcare sustainability. The BC-CfE works in close collaboration with key stakeholders, including government, health authorities, health care providers, academics, and the community to decrease the health burden of HIV/AIDS, hepatitis C and addictions across Canada and around the world. SOURCE British Columbia Centre for Excellence In HIV/AIDS View original content to download multimedia: Sign in to access your portfolio
